Gurpreet Sodhi, MD
Advanced Heart Failure and Transplant Cardiology · Sacramento, CANPI 1225264617
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $185,165 of the $240,789 with a category attached, or 76.9%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.1%. Reporting peaked in 2024 at $82,517 and has fallen 71.0% since, to $23,941 in 2025. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 521 payments — averaging $462.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$48K
- Boehringer Ingelheim$46K
- Pfizer$43K
- Actelion Pharmaceuticals US, Inc.$35K
- Abiomed$29K
- Lilly USA, LLC$19K
- plus $21K from 23 others
Across 16 payments — averaging $3874.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$52K
- Boehringer Ingelheim International GmbH$10K
What the payments were for
- Consulting fees$1,7161%
- Speaking & faculty fees$185,16577%
- Travel & lodging$28,45712%
- Food & beverage$25,34511%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 94 | $48,298 |
| Boehringer Ingelheim | 58 | $46,208 |
| Pfizer | 41 | $43,133 |
| Actelion Pharmaceuticals US, Inc. | 52 | $35,395 |
| Abiomed | 109 | $28,723 |
| Lilly USA, LLC | 20 | $18,525 |
| AstraZeneca | 20 | $7,576 |
| Abbott | 67 | $4,160 |
| Alnylam Pharmaceuticals Inc. | 6 | $2,922 |
| Bayer | 3 | $1,943 |
| Akcea Therapeutics, Inc. | 3 | $771 |
| Novartis | 13 | $694 |
| Atricure, Inc. | 5 | $366 |
| Edwards Lifesciences | 3 | $304 |
| Merck | 4 | $268 |
| Medtronic | 2 | $222 |
| Vifor Pharma, Inc. | 5 | $208 |
| Merit Medical Systems Inc | 1 | $192 |
| E.r. Squibb & Sons, L.L.C. | 2 | $171 |
| Heartflow, Inc. | 1 | $145 |
| Impulse Dynamics (USA) Inc. | 1 | $137 |
| Chiesi USA, Inc. | 1 | $125 |
| Kestra Medical Technology Services, Inc. | 1 | $106 |
| Inari Medical, Inc. | 1 | $59 |
| Amgen | 2 | $52 |
| Johnson & Johnson | 3 | $38 |
| Itamar Medical Inc | 1 | $23 |
| United Therapeutics Corporation | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$63,285
- LifeVest$45,893
- VYNDAQEL$42,556
- UPTRAVI$34,475
- OPSUMIT$34,354
- Impella$25,812
- WAINUA$7,051
- Kerendia$1,824
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$747
- HeartMate 3 Left Ventricular Assist Device$546
- CARDIOMEMS$505
- CardioMEMS HF System$310
- SYNERGY ABLATION SYSTEM$251
- ATRICLIP LAA EXCLUSION SYSTEM$251
- LEQVIO$247
- ENTRESTO$232
- EmboCath Plus Microcatheter$192
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$170
- HeartMate 3 Left Ventricular Dev$160
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$158
How this compares
$240,789 in reported general payments places this provider in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 62 | $1,517,784 |
| UptraviSelexipag | 30 | $672,336 |
| EntrestoSacubitril/Valsartan | 246 | $313,044 |
| JardianceEmpagliflozin | 199 | $230,523 |
| OpsumitMacitentan | 19 | $224,553 |
| AdempasRiociguat | 12 | $163,027 |
| EliquisApixaban | 96 | $117,704 |
| FarxigaDapagliflozin Propanediol | 62 | $57,938 |
| XareltoRivaroxaban | 20 | $15,115 |
| Sildenafil Citrate | 23 | $9,452 |
| Bumetanide | 139 | $7,593 |
| Praluent PenAlirocumab | 14 | $6,888 |
| Eplerenone | 71 | $4,058 |
| Metoprolol Succinate | 199 | $3,287 |
| Bisoprolol Fumarate | 73 | $2,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $43,133 | $1,635,489158 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $35,395 | $896,89049 claims |
| NovartisEntresto | $694 | $313,044246 claims |
| Boehringer IngelheimJardiance | $46,208 | $230,523199 claims |
| BayerAdempas | $1,943 | $163,02712 claims |
| AstraZenecaFarxiga | $7,576 | $57,93862 claims |
| Johnson & JohnsonXarelto | $38 | $15,11520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Sacramento
- Munir JanmohamedSacramento$314K
- John ChinSacramento$182K
- Nancy LuoSacramento$118K
- Zi Jian XuSacramento$67K
- Imo EbongSacramento$65K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.